Zentalis Pharmaceuticals’ (ZNTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Several other analysts have also commented on ZNTL. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, UBS Group lowered their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ:ZNTL opened at $1.81 on Thursday. The firm has a 50 day moving average of $2.04 and a 200 day moving average of $2.85. The company has a market capitalization of $128.99 million, a price-to-earnings ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter. On average, sell-side analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns bought 20,000 shares of the business’s stock in a transaction dated Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Corton Capital Inc. acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $32,000. Captrust Financial Advisors acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $33,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter worth $37,000. Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $37,000. Finally, Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $39,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.